Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET

Molecular Medicine Today

Volumn 4, Issue 12, 1998, Pages 532-539

  Andrews, Thomasin C ^a   Brooks, David J ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; HUMAN; HUNTINGTON CHOREA; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; BRAIN; DISEASE PROGRESSION; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031773636     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(98)01371-9     Document Type: Review

References (58)

1. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72:1993;971-983.
2. Furtado S.et al. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann. Neurol. 39:1996;132-136.
3. Davies S.W.et al. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet. 351:1998;131-133.
4. Lawrence, A.D. et al. Evidence for specific cognitive deficits in preclinical Huntington's disease, Brain (in press).
5. Alexander G.E., Delong M.R., Strick P.L. Parallel organisation of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9:1986;357-381.
6. Brandt, J. and Butters, N. (1996) Neuropsychological Assessment of Neuropsychiatric Disorders, Oxford University Press.
7. Hersch, S.M. and Ferrante, R.J. (1997) Neuropathology and pathophysiology of Huntington's disease, in Movement Disorders: Neurological Principles and Practice (Watts, R.L. and Koller, W.C., eds), pp. 503-518, McGraw-Hill.
8. Reiner A.et al. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. U. S. A. 85:1988;5733-5737.
9. Hedreen J.C., Folstein S.E. Early loss of neostriatal striosome neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 54:1995;105-120.
10. Lassen N.A., Ingvar D.H., Skinhoj E. Brain function and blood flow. Sci. Am. 239:1978;62-71.
11. 18FDG and computed tomographic scan. Ann. Neurol. 12:1982;425-434.
12. Hayden M.R.et al. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology. 36:1986;888-894.
13. Young A.B.et al. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann. Neurol. 20:1986;296-303.
14. Kuwert T.et al. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain. 113:1990;1405-1423.
15. Berent S.et al. Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function. Ann. Neurol. 23:1988;541-546.
16. Martin W.R.et al. Cortical glucose metabolism in Huntington's disease. Neurology. 42:1992;223-229.
17. Hayden M.R.et al. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Neurology. 37:1987;1441-1447.
18. Grafton S.T.et al. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Ann. Neurol. 28:1990;614-621.
19. Kuwert T.et al. Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease. J. Neurol. 241:1993;31-36.
20. Hasselbalch S.G.et al. Reduced regional cerebral blood flow in Huntington's disease studied by SPECT. J. Neurol. Neurosurg. Psychiatry. 55:1992;1018-1023.
21. Sax D.S.et al. Evidence of cortical metabolic dysfunction in early Huntington's disease by single-photon-emission computed tomography. Mov. Disord. 11:1996;671-677.
22. Weeks R.A.et al. Cortical control of movement in Huntington's disease. A PET activation study. Brain. 120:1997;1569-1578.
23. Bartenstein P.et al. Central motor processing in Huntington's disease. A PET study. Brain. 120:1997;1553-1567.
24. Reisine T.D.et al. Alterations in dopaminergic receptors in Huntington's disease. Life Sci. 21:1977;1123-1128.
25. Cross A., Rossor M. Dopamine D-1 and D-2 receptors in Huntington's disease. Eur. J. Pharmacol. 88:1983;223-229.
26. Leenders K.L., Frackowiak R.S., Quinn N., Marsden C.D. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Mov. Disord. 1:1986;69-77.
27. 11C-N-methyl-spiperone. Acta Neurol. Scand. 75:1987;87-94.
28. Brandt J.et al. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. J. Neuropsychiatry Clin. Neurosci. 2:1990;20-27.
29. Ichise M.et al. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. J. Nucl. Med. 34:1993;1274-1281.
30. Sedvall G.et al. Dopamine D1 receptor number-a sensitive PET marker for early brain degeneration in Huntington's disease. Eur. Arch. Psychiatry Clin. Neurosci. 243:1994;249-255.
31. Turjanski N.et al. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain. 118:1995;689-696.
32. Ginovart N.et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain. 120:1997;503-514.
33. Antonini A.et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain. 119:1996;2085-2095.
34. Weeks R.A., Piccini P., Harding A.E., Brooks D.J. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol. 40:1996;49-54.
35. 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. J. Cereb. Blood Flow Metab. 17:1997;943-949.
36. Holthoff V.A.et al. Positron emission tomography measures of benzodiazepine receptors in Huntington's disease. Ann. Neurol. 34:1993;76-81.
37. Tanahashi N.et al. Cerebral blood flow and cognitive testing correlate in Huntington's disease. Arch. Neurol. 42:1985;1169-1175.
38. Weinberger D.R.et al. Prefrontal cortical blood flow and cognitive function in Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 51:1988;94-104.
39. Goldberg T.E., Berman K.F., Mohr E., Weinberger D.R. Regional cerebral blood flow and cognitive function in Huntington's disease and schizophrenia. A comparison of patients matched for performance on a prefrontal-type task. Arch. Neurol. 47:1990;418-422.
40. Lawrence A.D.et al. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain. 121:1998;1343-1355.
41. Gerfen C.R.et al. D1 and D2 dopamine receptor-regulated gene expression of striato-nigral and striatopallidal neurons. Science. 250:1990;1429-1432.
42. Richfield E.K., O'Brien C.F., Eskin T., Shoulson I. Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neurosci. Lett. 132:1991;121-126.
43. Augood S.J., Faull R.L., Emson P.C. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol. 42:1997;215-221.
44. Joyce J.N., Lexow N., Bird E., Winokur A. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse. 2:1988;546-557.
45. Rappaport M.S.et al. Heterogeneous distribution of D1, D2 and D5 receptor mRNAs in monkey striatum. Brain Res. 616:1993;242-250.
46. Bird E.D., Iversen L.L. Neurochemical findings in Huntington's chorea. Essays Neurochem. Neuropharmacol. 1:1977;177-195.
47. Garcia Ruiz P.J.et al. Cerebrospinal fluid homovanillic acid is reduced in untreated Huntington's disease. Clin. Neuropharmacol. 18:1995;58-63.
48. Spokes E.G. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain. 103:1980;179-210.
49. 11C]SCH 23390 PET and the unified Huntington's disease rating scale can be used to monitor disease progression in asymptomatic Huntington's disease gene carriers. Soc. Neurosci. 23:1997;1912.
50. Grafton S.T.et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch. Neurol. 49:1992;1161-1167.
51. 11C]Raclopride striatal binding potential as a measure of Huntington's disease progression: implications for prospective neuroprotective studies. J. Nucl. Med. 39:1998;209.
52. Volkow N.D.et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J. Nucl. Med. 34:1993;609-613.
53. 11C]-raclopride. Ann. New York Acad. Sci. 695:1993;81-85.
54. Haque N.S., Borghesani P., Isacson O. Therapeutic strategies for Huntington's disease based on a molecular understanding of the disorder. Mol. Med. Today. 3:1997;175-183.
55. Aylward E.H.et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology. 44:1994;823-828.
56. Starkstein S.E.et al. Brain atrophy in Huntington's disease. A CT-scan study. Neuroradiology. 31:1989;156-159.
57. Terrence C.F., Delaney J.F., Alberts M.C. Computed tomography for Huntington's disease. Neuroradiology. 13:1977;173-175.
58. Starkstein S.E.et al. Neuropsychological and neuroradiological correlates in Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 51:1988;1259-1263.